Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer
NCT ID: NCT01190657
Last Updated: 2013-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1184 participants
INTERVENTIONAL
2010-05-31
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis
NCT01284647
A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium
NCT00125736
A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and Administration
NCT07139886
Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
NCT06151210
The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets
NCT06337604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Selbex 50mg (14 days)
Selbex
50mg/day, 3 times/day, for 14 days
Selbex 50mg (56 days)
Selbex
50mg/day, 3 times/day, for 56 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Selbex
50mg/day, 3 times/day, for 14 days
Selbex
50mg/day, 3 times/day, for 56 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Erosive lesions or flat lesions with thin white coating in acute gastritis, acute stage of chronic gastritis with over three lesions (including three lesions) by endoscopy prior to study in 3 days or diagnosed by clinical symptoms and signs;
3. Signed the informed consent forms.
2. Patients with significant cardiovascular, pulmonary, hepatic, renal or hemopoietic system primary disease
3. Patients with other digestive diseases.
4. Patients with operation on stomach and duodenum.
5. Patients administered with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids
6. Patients with severity trauma, surgery, infection and shock.
7. Patients with any kind of tumor
8. Women either pregnant or breast feeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yaozong Yuan
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese People's Liberation Army General Hospital of Beijing Military
Beijing, , China
Chongqing First People's Hospital
Chongqing, , China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, , China
Wuhan Union Hospital
Hubei, , China
Changsha Central Hospital
Hunan, , China
Hunan Provincial People's Hospital
Hunan, , China
Nanjing First Hospital
Jiangsu, , China
Nanjing General Hospital of Nanjing Military Command
Jiangsu, , China
The Second Affiliated Hospital of Nanjing Medical University
Jiangsu, , China
The Second Affiliated Hospital of Suzhou University
Jiangsu, , China
Wuxi #2 People's Hospital
Jiangsu, , China
Jilin University First Hospital
Jilin, , China
Shengjing Hospital of China Medical University
Liaoning, , China
Shanghai Changzheng Hospital
Shanghai, , China
Shanghai First People's Hospital
Shanghai, , China
Shanghai Renji Hospital
Shanghai, , China
Shanghai Ruijin Hospital
Shanghai, , China
Shanghai Sixth People's Hospital
Shanghai, , China
Shanghai Tenth People's Hospital
Shanghai, , China
Shanxi Provincial People's Hospital
Shanxi, , China
The Second Affiliated Hospital of the Medical College of Xi'an Jiaotong University
Shanxi, , China
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Sichuan, , China
The Affiliated Hospital of Luzhou Medical College
Sichuan, , China
Tongji Hospital
Sichuan, , China
Hangzhou Red Cross Hospital
Zhejiang, , China
The First Affiliated Hospital of Zhejiang University
Zhejiang, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P216
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.